Kerala Ayurveda Ltd

Kerala Ayurveda, a microcap in the Pharmaceuticals & Drugs sector, has recently seen a change in evaluation following strong Q2 FY24-25 financial results, including a notable increase in net profit and record net sales. However, long-term growth challenges persist, reflected in modest historical growth rates and a high debt profile.

Kerala Ayurveda has reached a 52-week high of Rs. 486.9, marking a 61.88% increase over the past year, significantly outperforming the Sensex. The stock has shown consistent gains, achieving a total return of 15.52% over three days, and is trading above key moving averages, indicating a strong bullish trend.

Kerala Ayurveda, a microcap in the pharmaceuticals sector, is trading near its 52-week high, maintaining a steady price throughout the session. The stock has outperformed its sector recently and has shown impressive annual growth, significantly exceeding the broader market's performance. It is also trading above key moving averages.

Kerala Ayurveda has achieved a new 52-week high of Rs. 460, reflecting strong performance in the pharmaceuticals sector. The stock has gained 8.23% over the last two days and has outperformed the Sensex significantly over the past year, indicating robust market interest and technical strength.

Kerala Ayurveda, a microcap in the pharmaceuticals sector, is trading near its 52-week high and has outperformed its sector today. The stock has shown strong momentum, trading above all major moving averages, and has increased by 52.95% over the past year, significantly surpassing the Sensex's growth.

Kerala Ayurveda, a microcap in the Pharmaceuticals & Drugs sector, has recently adjusted its evaluation amid strong second-quarter financial results, including significant net profit growth and notable sales. Despite a solid operating profit ratio and low debt-equity ratio, long-term growth concerns persist, reflected in its average Return on Capital Employed.

Kerala Ayurveda, a microcap in the pharmaceuticals sector, has recently adjusted its evaluation, reflecting its market position and performance. While the company reported positive financial metrics for Q2 FY24-25, it faces challenges with long-term sustainability due to high debt levels and modest operating profit growth.

Kerala Ayurveda has recently seen a revision in its score, reflecting its strong market performance and impressive growth metrics. The stock has been added to MarketsMOJO's list, following its achievement of a 52-week high and a notable outperformance against its sector. The company's consistent trading above key moving averages further underscores its robust position in the pharmaceuticals and drugs sector.

Kerala Ayurveda has recently seen a revision in its score, reflecting its strong market performance and position within the pharmaceuticals sector. The stock has outperformed its sector significantly, achieving an all-time high and trading above key moving averages. Additionally, it has been added to MarketsMOJO's list, underscoring its growth potential.

Kerala Ayurveda has experienced a revision in its score by MarketsMOJO, reflecting the company's impressive net profit growth and strong sales performance. Despite facing challenges in long-term fundamentals, the stock has been added to MarketsMOJO's list, highlighting its recent bullish technical trend and consistent outperformance against the BSE 500 index.

Kerala Ayurveda has reached a new 52-week high, reflecting its strong market performance and significant gains over the past year. Following a recent adjustment in its evaluation, the stock has been added to MarketsMOJO's list, highlighting its resilience and ability to outperform both its sector and the broader market.

Kerala Ayurveda has recently undergone a revision in its score, reflecting the stock's fluctuating performance amid market volatility. Despite a recent decline, the company has demonstrated impressive growth over the past year, significantly outpacing the broader market. Additionally, it has been added to MarketsMOJO's list, highlighting its potential in the pharmaceuticals sector.

Kerala Ayurveda has recently experienced a revision in its score by MarketsMOJO, reflecting concerns over its long-term fundamental strength and high valuation metrics. Despite a notable return over the past year and impressive recent profit growth, the stock's overall evaluation has been adjusted due to persistent financial challenges. The company has been added to MarketsMOJO's list, indicating ongoing scrutiny of its market position.

Kerala Ayurveda has recently seen a revision in its score by MarketsMOJO, reflecting a notable shift in its evaluation. The company reported impressive growth in net profit and achieved record net sales, contributing to a mildly bullish technical outlook. However, concerns remain regarding its long-term fundamentals and high debt levels.

Kerala Ayurveda, a microcap pharmaceutical company, has reported strong financial results for the quarter ending September 2024. Despite a 'Strong Sell' call by MarketsMOJO, the company's score has improved significantly in the last three months. Key factors contributing to this include a 1610.7% growth in Profit After Tax and a significant increase in Net Sales. The company's debt management has also shown improvement.

Kerala Ayurveda, a microcap pharmaceutical company, has announced its financial results for the quarter ended March 2024. Despite receiving a 'Sell' call from MarketsMOJO, the company has shown positive performance with consistent scores and increasing net sales for the past five quarters. However, increased interest cost and borrowing require attention.

Kerala Ayurveda, a microcap pharma company, has received a 'Hold' rating from MarketsMOJO after reporting strong results in the quarter ending March 2024. The company has a strong cash position and bullish technical indicators, but its weak long-term fundamentals and high valuation make it a 'Hold' for now.

Kerala Ayurveda, a microcap pharma company, was downgraded to 'Sell' by MarketsMOJO on August 2, 2024 due to weak long-term fundamentals, high debt-to-equity ratio, and expensive valuation. However, it has shown positive signs in the last quarter and has consistently outperformed the BSE 500 in the past 3 years.

Kerala Ayurveda, a microcap company in the pharma industry, has seen a surge in its stock price, reaching a 52-week high of Rs. 417 on July 9th, 2024. The stock has been performing well, trading higher than the moving averages and outperforming the Sensex in the past year. With its focus on traditional Ayurvedic medicines, Kerala Ayurveda has gained a loyal customer base and is a company to watch in the pharma sector.